Publications by authors named "Thomas Aebi"
Objectives: To assess the association between overweight/obesity and anemia in early childhood in Tajikistan.
Methods: Using a two-stage-cluster sampling, a representative sample of 1342 children (48.7% girls) aged 25-60 months was included in a nationwide survey in Tajikistan in 2009.
Article Synopsis
- The RTS,S/AS malaria vaccine is being studied for inclusion in the WHO's Expanded Programme on Immunization, with safety and effectiveness evaluated over 20 months after the initial nine-month surveillance.
- In a Tanzanian trial with 340 infants, both RTS,S/AS02(D) and the hepatitis B vaccine were administered, revealing a similar safety profile with no significant adverse vaccine-related events.
- By month 20, 71.8% of RTS,S recipients had protective antibody levels against malaria, showing a vaccine efficacy of approximately 50.7% at 12 months, though efficacy was less clear at 18 months with a rate of 26.7%.
Background: This trial was conducted to evaluate the safety and immunogenicity of two virosome formulated malaria peptidomimetics derived from Plasmodium falciparum AMA-1 and CSP in malaria semi-immune adults and children.
Methods: The design was a prospective randomized, double-blind, controlled, age-deescalating study with two immunizations. 10 adults and 40 children (aged 5-9 years) living in a malaria endemic area were immunized with PEV3B or virosomal influenza vaccine Inflexal®V on day 0 and 90.
Bagamoyo Research and Training Centre (BRTC), a branch of the Ifakara Health Institute (IHI), established in late 2004, has evolved into a leading site in performing high-quality Phase II and Phase III malaria vaccine and drug trials according to ICH/GCP standards. Several Phase II and III trials and assessments of interventions focused on better diagnosis, treatment and prevention of malaria have been completed successfully. Expansion into the areas of TB, with the set up of a new BSL-3, and HIV/AIDS marks the commitment of the site to developing into a regional centre of excellence for both clinical trials and epidemiological research.
View Article and Find Full Text PDFBackground: The RTS,S/AS malaria vaccine is being developed for delivery through the World Health Organization's Expanded Program on Immunization (EPI). We assessed the feasibility of integrating RTS,S/AS02D into a standard EPI schedule for infants.
Methods: In this phase 2B, single-center, double-blind, controlled trial involving 340 infants in Bagamoyo, Tanzania, we randomly assigned 340 infants to receive three doses of either the RTS,S/AS02D vaccine or the hepatitis B vaccine at 8, 12, and 16 weeks of age.